Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more) Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astellas Pharma ADR Representing 1 Ord Shs ALPMY

Healthcare
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Recent & Breaking News (PINL:ALPMY)

U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia

PR Newswire October 10, 2017

Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

PR Newswire October 10, 2017

Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Business Wire September 14, 2017

U.S. FDA Accepts for Review Astellas' Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

PR Newswire September 12, 2017

First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid Leukemia

PR Newswire August 21, 2017

Astellas Announces Wind-Down of Agensys Research Operations

PR Newswire July 26, 2017

U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia

PR Newswire July 20, 2017

Astellas Submits Supplemental New Drug Application for Mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

PR Newswire June 29, 2017

The Astellas Oncology C3 Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants

PR Newswire June 20, 2017

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

Business Wire June 9, 2017

Astellas Announces Oncology Portfolio Updates

PR Newswire May 17, 2017

Astellas Completes Acquisition of Ogeda SA

PR Newswire May 16, 2017

Astellas Names Shontelle Dodson Senior Vice President and Head of Medical Affairs Americas

PR Newswire May 11, 2017

Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical Study Protocol 8273-CL-0302

PR Newswire May 10, 2017

Astellas Announces Key Leadership Promotions in Development Organization

PR Newswire April 28, 2017

Use of Extended-Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) and Preventing Recurrence[1]

PR Newswire Europe Non Regulatory April 23, 2017

New Study Reveals the Impact of Clostridium difficile Infection (CDI) on the Health Service is Equivalent to an Additional 10,670 Bed Days a Year

PR Newswire Europe Non Regulatory April 20, 2017

Astellas to Acquire Ogeda SA

PR Newswire April 2, 2017

Astellas to Present at J.P. Morgan Healthcare Conference

PR Newswire December 21, 2016

Astellas Completes Acquisition of Ganymed Pharmaceuticals

PR Newswire December 21, 2016